33.23
0.48 (1.47%)
| Previous Close | 32.75 |
| Open | 32.92 |
| Volume | 78,486 |
| Avg. Volume (3M) | 655,279 |
| Market Cap | 1,509,835,648 |
| Price / Earnings (TTM) | 830.75 |
| Price / Sales | 1.30 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 1.87% |
| Operating Margin (TTM) | -4.31% |
| Diluted EPS (TTM) | 0.460 |
| Quarterly Revenue Growth (YOY) | 9.60% |
| Quarterly Earnings Growth (YOY) | 55.40% |
| Total Debt/Equity (MRQ) | 30.69% |
| Current Ratio (MRQ) | 1.38 |
| Operating Cash Flow (TTM) | 163.69 M |
| Levered Free Cash Flow (TTM) | 122.12 M |
| Return on Assets (TTM) | 0.35% |
| Return on Equity (TTM) | 1.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Omnicell, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.30 |
|
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.78% |
| % Held by Institutions | 104.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 31 Dec 2025 | 1,142,555 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Benchmark, 80.56%) | Buy |
| 60.00 (Keybanc, 80.56%) | Buy | |
| Median | 56.00 (68.52%) | |
| Low | 49.00 (Piper Sandler, 47.46%) | Buy |
| Average | 55.25 (66.27%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 45.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 06 Feb 2026 | 49.00 (47.46%) | Buy | 37.07 |
| Benchmark | 02 Feb 2026 | 60.00 (80.56%) | Buy | 48.70 |
| Keybanc | 08 Jan 2026 | 60.00 (80.56%) | Buy | 50.59 |
| Wells Fargo | 05 Jan 2026 | 52.00 (56.49%) | Buy | 46.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results |
| 13 Jan 2026 | Announcement | Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |